This tag follows court cases that shape the peptide and biologic drug business, from product-liability claims to contract fights between drug developers.
The largest is MDL 3094 in the U.S. District Court for the Eastern District of Pennsylvania, where Judge Karen S. Marston oversees consolidated gastrointestinal-injury claims, including gastroparesis, against Novo Nordisk (Ozempic, Wegovy, Rybelsus) and Eli Lilly (Trulicity, Mounjaro). The court held a Rule 702 evidentiary hearing on cross-cutting expert issues from September 14 to 18, 2026. Vision-loss claims tied to non-arteritic anterior ischemic optic neuropathy (NAION) are consolidated separately in MDL 3163 in the same court.
Contract disputes land here too. On September 24, 2026, a federal jury in Northern California found that Lilly breached the implied covenant of good faith in its rezpegaldesleukin license with Nektar Therapeutics and awarded Nektar $90 million plus interest, subject to post-trial proceedings.
See #glp-1, #eli-lilly, and #novo-nordisk for adjacent threads.
A federal jury in the Northern District of California found on Thursday, September 24, 2026 that Eli Lilly breached the implied covenant of good faith and fair dealing in its license agreement with Nektar Therapeutics for rezpegaldesleukin (rezpeg), an autoimmune disease drug, and awarded Nektar $90 million in damages plus interest to be set by the court. Nektar filed the suit in August 2023, and the trial began on September 8. The verdict remains subject to post-trial proceedings, and any judgment may be appealed.
The GLP-1 mass tort litigation (MDL 3094) before Judge Karen Marston in the Eastern District of Pennsylvania now includes 3,363 cases alleging gastroparesis and other injuries. Expert discovery closed in late March, with Daubert motions due April 28 and summary judgment motions due April 30. A Science Day on vision loss claims is set for June 2.
Over 3,546 lawsuits are now consolidated in two federal MDLs — one for gastroparesis and one for NAION vision loss. On March 3, a federal judge appointed lead counsel for the NAION MDL. Studies show semaglutide users face a fourfold increase in NAION risk, with vision loss claims now generating more legal attention than earlier gastroparesis cases.